JP2024516605A - コロナウイルス感染を処置するための新規組成物及び方法 - Google Patents

コロナウイルス感染を処置するための新規組成物及び方法 Download PDF

Info

Publication number
JP2024516605A
JP2024516605A JP2023564191A JP2023564191A JP2024516605A JP 2024516605 A JP2024516605 A JP 2024516605A JP 2023564191 A JP2023564191 A JP 2023564191A JP 2023564191 A JP2023564191 A JP 2023564191A JP 2024516605 A JP2024516605 A JP 2024516605A
Authority
JP
Japan
Prior art keywords
ace2
sars
cells
cov
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023564191A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024516605A5 (https=
Inventor
スダ ラオ，
Original Assignee
ザ・カウンシル・オヴ・ザ・クイーンズランド・インスティテュート・オヴ・メディカル・リサーチ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2021901169A external-priority patent/AU2021901169A0/en
Application filed by ザ・カウンシル・オヴ・ザ・クイーンズランド・インスティテュート・オヴ・メディカル・リサーチ filed Critical ザ・カウンシル・オヴ・ザ・クイーンズランド・インスティテュート・オヴ・メディカル・リサーチ
Publication of JP2024516605A publication Critical patent/JP2024516605A/ja
Publication of JP2024516605A5 publication Critical patent/JP2024516605A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/15—Oximes (>C=N—O—); Hydrazines (>N—N<); Hydrazones (>N—N=) ; Imines (C—N=C)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/485—Exopeptidases (3.4.11-3.4.19)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/17—Metallocarboxypeptidases (3.4.17)
    • C12Y304/17023—Angiotensin-converting enzyme 2 (3.4.17.23)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Vascular Medicine (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2023564191A 2021-04-20 2022-04-20 コロナウイルス感染を処置するための新規組成物及び方法 Pending JP2024516605A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
AU2021901169 2021-04-20
AU2021901169A AU2021901169A0 (en) 2021-04-20 Novel compositions and methods for treating coronavirus infections
AU2022900358A AU2022900358A0 (en) 2022-02-18 Novel compositions and methods for treating coronavirus infections
AU2022900358 2022-02-18
PCT/AU2022/050363 WO2022221920A1 (en) 2021-04-20 2022-04-20 Novel compositions and methods for treating coronavirus infections

Publications (2)

Publication Number Publication Date
JP2024516605A true JP2024516605A (ja) 2024-04-16
JP2024516605A5 JP2024516605A5 (https=) 2025-08-06

Family

ID=83723477

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023564191A Pending JP2024516605A (ja) 2021-04-20 2022-04-20 コロナウイルス感染を処置するための新規組成物及び方法

Country Status (8)

Country Link
US (1) US20240352072A1 (https=)
EP (1) EP4326757A4 (https=)
JP (1) JP2024516605A (https=)
KR (1) KR20240027579A (https=)
AU (1) AU2022260860A1 (https=)
CA (1) CA3216329A1 (https=)
IL (1) IL307872A (https=)
WO (1) WO2022221920A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024020646A1 (en) * 2022-07-27 2024-02-01 The Council Of The Queensland Institute Of Medical Research Methylation biomarker for infection resistance

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002525108A (ja) * 1998-09-30 2002-08-13 ミレニアム・フアーマシユーチカルズ・インコーポレーテツド アンジオテンシン変換酵素相同物およびその使用
CN111920806A (zh) * 2020-07-14 2020-11-13 中日友好医院(中日友好临床医学研究所) 苹果酸舒尼替尼在制备抑制冠状病毒的药物中的应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002012471A2 (en) * 2000-08-09 2002-02-14 Millennium Pharmaceuticals, Inc. Angiotensin converting enzyme homolog and uses therefor
WO2007030937A2 (en) * 2005-09-16 2007-03-22 Institut De Recherches Cliniques De Montreal/I.R.C.M. Screening proteinase modulators using a chimeric protein and ski-i proprotein convertase substrates and inhibitors
CA2652247C (en) * 2006-05-08 2015-11-17 Adaerata, Limited Partnership Chimeric pcsk9 proteins, cells comprising same, and assays using same
US20230152316A1 (en) * 2020-03-19 2023-05-18 Massachusetts Institute Of Technology Sars-cov2 spike protein binding peptides
WO2021195723A1 (en) * 2020-04-03 2021-10-07 The Council Of The Queensland Institute Of Medical Research "methods for treatment of coronavirus infections"
CA3179872A1 (en) * 2020-04-22 2021-10-28 Dana-Farber Cancer Institute, Inc. Antiviral structurally-stabilized ace2 helix 1 peptides and uses thereof
WO2022075921A1 (en) * 2020-10-08 2022-04-14 Hummingbird Bioscience Holdings Limited Sars-cov-2 spike protein antigen-binding molecules

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002525108A (ja) * 1998-09-30 2002-08-13 ミレニアム・フアーマシユーチカルズ・インコーポレーテツド アンジオテンシン変換酵素相同物およびその使用
CN111920806A (zh) * 2020-07-14 2020-11-13 中日友好医院(中日友好临床医学研究所) 苹果酸舒尼替尼在制备抑制冠状病毒的药物中的应用

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
SCHUTZ D. ET AL., ADV DRUG DELIV REV, vol. 167, JPN6026010982, December 2020 (2020-12-01), pages 47 - 65, ISSN: 0005822601 *

Also Published As

Publication number Publication date
CA3216329A1 (en) 2022-10-27
US20240352072A1 (en) 2024-10-24
KR20240027579A (ko) 2024-03-04
WO2022221920A1 (en) 2022-10-27
IL307872A (en) 2023-12-01
AU2022260860A1 (en) 2023-12-07
EP4326757A1 (en) 2024-02-28
EP4326757A4 (en) 2025-07-09

Similar Documents

Publication Publication Date Title
JP2023518038A5 (https=)
CA2523875A1 (en) Sars virus nucleotide and amino acid sequences and uses thereof
JP4807526B2 (ja) 呼吸器疾患の抗ウイルス療法のためのインターフェロン−β
US11364276B2 (en) Antiviral peptides for treatment of the middle east respiratory syndrome
US20240218059A1 (en) TGF-Beta 1 INHIBITORS FOR PREVENTING AND TREATING SARS-COV-2
US20220213143A1 (en) Method of treatment
CN109593123B (zh) 一种衍生自rps23rg1的多肽及其应用
JP2024516605A (ja) コロナウイルス感染を処置するための新規組成物及び方法
CN117677631A (zh) 用于治疗冠状病毒感染的新型组合物和方法
KR102628158B1 (ko) 제2형 중증급성호흡기증후군 코로나바이러스에 중화 활성을 갖는 펩타이드
CN116075298B (zh) 用于治疗冠状病毒感染的方法
DK3202413T3 (en) MODIFIED PEPTIDES AND ITS APPLICATION FOR THE TREATMENT OF AUTOIMMUNE DISEASES
KR101783030B1 (ko) C형 간염 바이러스 감염 또는 감염과 관련된 질병의 예방 또는 치료용 약학 조성물
WO2018217075A1 (en) Peptides and uses therefor as antiviral agents
US20240294587A1 (en) K-ras inhibitor
JP2023546383A (ja) アネキシンａ５組成物及び方法
US8252293B2 (en) Binding domain of Plasmodium reticulocyte binding proteins
US20230355725A1 (en) Neil2 protein therapy for treatment of viral infection
Camero et al. Characterization of a Cryptosporidium parvum gene encoding a protein with homology to long chain fatty acid synthetase
JP7185874B2 (ja) 抗ウイルス剤としてのラビリントペプチン
CN116981946A (zh) Lrrc4家族模拟分子及其诊断用途
Pratelli Ultrastructural and immunolocalization studies on the interactions occurring between IntraFlagellar Transport components and the ciliary tip structures during IFT trains turnaround in Chlamydomonas flagella
WO2022066798A1 (en) Interferon tau fc-fusion proteins and methods for treating coronavirus infections
Schäfer Genetic variation and functional analysis of the cardiomedin gene
JP2008523068A (ja) 有機化合物の使用

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250421

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250421

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250729

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20260318

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20260324